High-Density Surface EMG Guided Botulinum Toxin Injection - Effect on the Compound Muscle Action Potential Recorded from the Extensor Digitorum Brevis Muscle

High-Density Surface EMG Guided Botulinum Toxin Injection - Effect on the Compound Muscle Action Potential Recorded from the Extensor Digitorum Brevis Muscle - HD-sEMG guided Botulinum Toxin injection

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON30657

Enrollment

Registered

2007-06-12

Start date

2007-03-15

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

n.a.

Interventions

On the study side the injection of BTXA takes place under guides of HDsEMG. On the control side this is done without the knowledge of where the endplate position is.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Obtainable CMAP from the extensor digitorum brevis muscle

Exclusion criteria

Exclusion criteria: neuromuscular disorders

Design outcomes

Primary

Measure	Time frame
Reduction of the compound muscle action potential (CMAP) measured from the extensor digitorum brevis (EDB) compared between study and control side after 2 weeks.	—

Secondary

Measure	Time frame
Timecoarse after 8 en 12 weeks is evaluated to see if this differs between the two sides.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)